, /PRNewswire/ -- A team of investigators at City of Hope funded by the Prostate Cancer Foundation (PCF) reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor (CAR) T cell therapy. The results of their first-in-human phase 1 clinical trial, which also showed promising therapeutic activity, were published today in . "This represents an important advance against metastatic castration-resistant prostate cancer (mCRPC) which continues to claim more than 30,000 men's lives each year," said , PhD, Executive Vice President, Chief Science Officer and Lori and Michael Milken Chair of the Prostate Cancer Foundation.
"PCF is proud to invest in this crucial work which advances our mission to end death and suffering from prostate cancer, and we look forward to seeing their future progress with PSCA-directed CAR T cell therapy." , PhD, City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and team developed CAR T cells that target prostate stem cell antigen (PSCA), which is highly expressed in prostate cancer. The phase 1 trial treated 14 PSCA-positive patients with mCRPC, which had spread beyond the prostate and no longer responded to hormone treatment, using the PSCA-directed CAR T-cell therapy.
Patients' own immune system T cells were reprogrammed in a laboratory with a CAR to recognize and attack the PSCA protein on the surface of cancer cells. The CAR T cells were then infused back into the p.
